159 related articles for article (PubMed ID: 26622627)
1. Obligate anaerobic
Yu B; Shi L; Zhang BZ; Zhang KE; Peng X; Niu HB; Qu JL
Oncol Lett; 2015 Aug; 10(2):1069-1074. PubMed ID: 26622627
[TBL] [Abstract][Full Text] [Related]
2. 'Obligate' anaerobic
Li CX; Yu B; Shi L; Geng W; Lin QB; Ling CC; Yang M; Ng KT; Huang JD; Man K
Oncol Lett; 2017 Jan; 13(1):177-183. PubMed ID: 28123538
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Neuroblastoma with an Engineered "Obligate" Anaerobic
Ning BT; Yu B; Chan S; Chan JL; Huang JD; Chan GC
J Cancer; 2017; 8(9):1609-1618. PubMed ID: 28775780
[No Abstract] [Full Text] [Related]
4. Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma.
Guo ZL; Yu B; Ning BT; Chan S; Lin QB; Li JC; Huang JD; Chan GC
J Hematol Oncol; 2015 Aug; 8():99. PubMed ID: 26286454
[TBL] [Abstract][Full Text] [Related]
5. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy.
Chen F; Zang Z; Chen Z; Cui L; Chang Z; Ma A; Yin T; Liang R; Han Y; Wu Z; Zheng M; Liu C; Cai L
Biomaterials; 2019 Sep; 214():119226. PubMed ID: 31174068
[TBL] [Abstract][Full Text] [Related]
6. Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain.
Yu B; Yang M; Shi L; Yao Y; Jiang Q; Li X; Tang LH; Zheng BJ; Yuen KY; Smith DK; Song E; Huang JD
Sci Rep; 2012; 2():436. PubMed ID: 22666539
[TBL] [Abstract][Full Text] [Related]
7. Toxicology and efficacy of tumor-targeting
Zhang Y; Cao W; Toneri M; Zhang N; Kiyuna T; Murakami T; Nelson SD; Dry SM; Li Y; Li S; Wang X; Ma H; Singh AS; Eilber FC; Hoffman RM; Zhao M
Oncotarget; 2017 Aug; 8(33):54616-54628. PubMed ID: 28903369
[No Abstract] [Full Text] [Related]
8. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
9. Targeted IFNγ induction by a genetically engineered
Hua Z; Wu S; Zhang Y; Wang X; Cui J; Li Y; Yang C; Zhai M; Deng B; Yu B; Huang JD; Wang Z; Zhou J
Front Med (Lausanne); 2023; 10():1284120. PubMed ID: 38020179
[TBL] [Abstract][Full Text] [Related]
10. Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-Cancer
Yang S; Zhao W; Zhu M; Hu H; Wang W; Zang Z; Jin M; Bi J; Huang J; Liu C; Li X; Yin P; Li N
Front Immunol; 2021; 12():712936. PubMed ID: 34489962
[TBL] [Abstract][Full Text] [Related]
11. Salmonella typhimurium A1-R tumor targeting in immunocompetent mice is enhanced by a traditional Chinese medicine herbal mixture.
Zhang Y; Zhang N; Su S; Hoffman RM; Zhao M
Anticancer Res; 2013 May; 33(5):1837-43. PubMed ID: 23645728
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice.
Zhao M; Yang M; Ma H; Li X; Tan X; Li S; Yang Z; Hoffman RM
Cancer Res; 2006 Aug; 66(15):7647-52. PubMed ID: 16885365
[TBL] [Abstract][Full Text] [Related]
13. Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.
Coutermarsh-Ott SL; Broadway KM; Scharf BE; Allen IC
Oncotarget; 2017 May; 8(20):33601-33613. PubMed ID: 28431394
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
15. An obligatory anaerobic
Yang M; Xu J; Wang Q; Zhang AQ; Wang K
Oncol Lett; 2018 Mar; 15(3):3918-3922. PubMed ID: 29456740
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.
Zhao M; Geller J; Ma H; Yang M; Penman S; Hoffman RM
Proc Natl Acad Sci U S A; 2007 Jun; 104(24):10170-4. PubMed ID: 17548809
[TBL] [Abstract][Full Text] [Related]
17. Targeting Orthotopic Glioma in Mice with Genetically Engineered Salmonella typhimurium.
Wen M; Jung S; Moon KS; Jiang SN; Li SY; Min JJ
J Korean Neurosurg Soc; 2014 Mar; 55(3):131-5. PubMed ID: 24851147
[TBL] [Abstract][Full Text] [Related]
18. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity.
Chen G; Wei DP; Jia LJ; Tang B; Shu L; Zhang K; Xu Y; Gao J; Huang XF; Jiang WH; Hu QG; Huang Y; Wu Q; Sun ZH; Zhang JF; Hua ZC
Cancer Sci; 2009 Dec; 100(12):2437-43. PubMed ID: 19793349
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
